Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Alexey N Boyko & Olga V Boyko. (2018) Cladribine tablets’ potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degenerative Neurological and Neuromuscular Disease 8, pages 35-44.
Read now
Read now
Giancarlo Comi, Hans-Peter Hartung, Nuwan C Kurukulasuriya, Steven J Greenberg & Matthew Scaramozza. (2013)
Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis. Expert Opinion on Pharmacotherapy 14:1, pages 123-136.
Read now
Read now
Kenneth P Johnson. (2010) Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Therapeutics and Clinical Risk Management 6, pages 153-172.
Read now
Read now
Claudio Gasperini, Serena Ruggieri & Carlo Pozzilli. (2010) Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets. Therapeutics and Clinical Risk Management 6, pages 391-399.
Read now
Read now
Julie A Murphy, Jacklyn A Harris & Andrew J Crannage. (2010) Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment 6, pages 619-625.
Read now
Read now
Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, Olaf Stüve & Bernd C Kieseier. (2010) Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine. Drug Design, Development and Therapy 4, pages 117-126.
Read now
Read now
Jack C Sipe. (2010) Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Review of Neurotherapeutics 10:3, pages 365-375.
Read now
Read now
Patricia Hentosh & Dennis M Peffley. (2010) The cladribine conundrum: deciphering the drug's mechanism of action. Expert Opinion on Drug Metabolism & Toxicology 6:1, pages 75-81.
Read now
Read now
Articles from other publishers (55)
Gavin Giovannoni & Joela Mathews. (2022) Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review. Neurology and Therapy 11:2, pages 571-595.
Crossref
Crossref
S. V. Petrov, O. V. Boyko & A. N. Boyko. (2022) Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice. Neurology, Neuropsychiatry, Psychosomatics 14:1, pages 22-25.
Crossref
Crossref
Xuelin Feng, Zubiao Song, Mengli Wu, Yanmei Liu, Sushan Luo, Chongbo Zhao & Weixi Zhang. (2021) Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. Frontiers in Neurology 12.
Crossref
Crossref
Vicki E Maltby, Rodney A Lea, Mastura Monif, Marzena J Fabis-Pedrini, Katherine Buzzard, Tomas Kalincik, Allan G Kermode, Bruce Taylor, Suzanne Hodgkinson, Pamela McCombe, Helmut Butzkueven, Michael Barnett & Jeannette Lechner-Scott. (2021) Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). JMIR Research Protocols 10:10, pages e24969.
Crossref
Crossref
Donald J. AbrahamWilliam A. Denny. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
74
.
Najme Dastani, Ali Arab & Heidar Raissi. (2021) DFT study of Ni-doped graphene nanosheet as a drug carrier for multiple sclerosis drugs. Computational and Theoretical Chemistry 1196, pages 113114.
Crossref
Crossref
Marjan Nasrabadi, Ali Morsali & S. Ali Beyramabadi. (2020) An applied quantum-chemical model for genipin-crosslinked chitosan (GCS) nanocarrier. International Journal of Biological Macromolecules 165, pages 1229-1240.
Crossref
Crossref
Najme Dastani, Ali Arab & Heidar Raissi. (2020) DFT computational study towards investigating Cladribine anticancer drug adsorption on the graphene and functionalized graphene. Structural Chemistry 31:5, pages 1691-1705.
Crossref
Crossref
S. V. Petrov, O. V. Boyko & A. N. Boyko. (2020) Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice. Neurology, Neuropsychiatry, Psychosomatics 12:1S, pages 25-28.
Crossref
Crossref
M.V. Zhuravleva, M.V. Davydovskaya, E.V. Luchinina, T.V. Shelekhova, D.O. Kurguzova & S.Yu. Serebrova. (2020) Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:8, pages 148.
Crossref
Crossref
Stuart Cook, Thomas Leist, Giancarlo Comi, Xavier Montalban, Gavin Giovannoni, Axel Nolting, Christine Hicking, Andrew Galazka & Elke Sylvester. (2019) Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Multiple Sclerosis and Related Disorders 29, pages 157-167.
Crossref
Crossref
Mina Lotfi, Ali Morsali & Mohammad Reza Bozorgmehr. (2018) Comprehensive quantum chemical insight into the mechanistic understanding of the surface functionalization of carbon nanotube as a nanocarrier with cladribine anticancer drug. Applied Surface Science 462, pages 720-729.
Crossref
Crossref
Yara Dadalti Fragoso, Tarso Adoni, Joseph B. Bidin Brooks, Alessandro Finkelsztejn, Paulo Diniz da Gama, Anderson K. Grzesiuk, Vanessa Daccach Marques, Monica Fiuza K. Parolin, Henry K. Sato, Daniel Lima Varela & Claudia Cristina F. Vasconcelos. (2018) Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children. Neurology and Therapy 7:2, pages 207-232.
Crossref
Crossref
Gavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Giancarlo Comi, Fernando Dangond, Abidemi K Adeniji & Patrick Vermersch. (2017) Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal 24:12, pages 1594-1604.
Crossref
Crossref
Serkan Yavuz, Aysu Çetin, Atilla Akdemir, Doğukan Doyduk, Ali Dişli, Gurbet Çelik Turgut, Alaattin Şen & Yılmaz Yıldırır. (2017) Synthesis and Functional Investigations of Computer Designed Novel Cladribine-Like Compounds for the Treatment of Multiple Sclerosis. Archiv der Pharmazie 350:11, pages 1700185.
Crossref
Crossref
Radojka M. Savic, Ana M. Novakovic, Marianne Ekblom, Alain Munafo & Mats O. Karlsson. (2017) Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Clinical Pharmacokinetics 56:10, pages 1245-1253.
Crossref
Crossref
Gavin Giovannoni. (2017) Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics 14:4, pages 874-887.
Crossref
Crossref
Laura Kaliyeva, Shingis Zhumagali, Nuriya Akhmetova, Amir Karton & Robert J. O'Reilly. (2016) Stability of the chlorinated derivatives of the DNA/RNA nucleobases, purine and pyrimidine toward radical formation via homolytic CCl bond dissociation. International Journal of Quantum Chemistry 117:4.
Crossref
Crossref
V Singh, C K Prajeeth, V Gudi, K Bénardais, E V Voss & M Stangel. (2013) 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clinical and Experimental Immunology 173:2, pages 288-297.
Crossref
Crossref
Giancarlo Comi, Stuart D. Cook, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg S?rensen, Patrick Vermersch, Anthony C. Hamlett, Vissia Viglietta & Steven J. Greenberg. (2012) MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of Neurology 260:4, pages 1136-1146.
Crossref
Crossref
Naveen Mulakayala, Pallavi Rao, Javed Iqbal, Rakeshwar Bandichhor & Srinivas Oruganti. (2013) Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview. European Journal of Medicinal Chemistry 60, pages 170-186.
Crossref
Crossref
Patrycja Chylinska-Wrzos, Ewelina Wawryk-Gawda, Marta Lis-Sochocka, Marian Jedrych, Miroslaw Lancut, Kamila Bulak, Joanna Leszcz-Stankiewicz & Barbara Jodlowska-Jedrych. (2013) The intrinsic or the extrinsic pathways of apoptosis in the epidermis after cladribine application?. Journal of Biomedical Science and Engineering 06:03, pages 265-272.
Crossref
Crossref
Teri L. SchreinerAugusto Miravalle. (2012) Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine. Journal of Central Nervous System Disease 4, pages JCNSD.S5128.
Crossref
Crossref
Shehzad Ali, Noman Paracha, Stuart Cook, Gavin Giovannoni, Giancarlo Comi, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Steven Greenberg, David A. Scott & Alexandre Joyeux. (2012) Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. Clinical Drug Investigation 32:1, pages 15-27.
Crossref
Crossref
Clemens Warnke, Verena I. Leussink, Norbert Goebels, Orhan Aktas, Alexey Boyko, Bernd C. Kieseier & Hans-Peter Hartung. (2012) Cladribine as a therapeutic option in multiple sclerosis. Clinical Immunology 142:1, pages 68-75.
Crossref
Crossref
Gavin Giovannoni & Stuart D. Cook. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
358
369
.
. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
300
582
.
S Cook, P Vermersch, G Comi, G Giovannoni, K Rammohan, P Rieckmann, P Soelberg Sørensen, A Hamlett, M Miret, J Weiner, V Viglietta, B Musch & SJ Greenberg. (2011) Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Multiple Sclerosis Journal 17:5, pages 578-593.
Crossref
Crossref
Karen Schreiber & Per Soelberg Sorensen. (2011) Cladribine in the treatment of multiple sclerosis. Clinical Investigation 1:2, pages 317-326.
Crossref
Crossref
Colleen E. Miller & Margaret A. Umhauer. (2011) Emerging Oral Therapies for Multiple Sclerosis. Journal of Neuroscience Nursing 43:1, pages 3-14.
Crossref
Crossref
Jacek Losy & Alicja Kalinowska-Łyszczarz. (2011) Emerging disease-modifying oral therapies for multiple sclerosis. Journal of Neuroimmunology 231:1-2, pages 15-22.
Crossref
Crossref
Francesca BagnatoIstvan Pirko. (2011) Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis. What Role for Cladribine?. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6456.
Crossref
Crossref
Thomas P. Leist & Robert Weissert. (2011) Cladribine. Clinical Neuropharmacology 34:1, pages 28-35.
Crossref
Crossref
Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinka & Jörg Kraus. (2011) Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. Drug Discovery Today 16:1-2, pages 8-21.
Crossref
Crossref
K. Mitosek-Szewczyk, Z. Stelmasiak, H. Bartosik-Psujek & E. Belniak. (2010) Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurologica Scandinavica 122:6, pages 409-413.
Crossref
Crossref
Amy Perrin Ross & Ben W. Thrower. (2010) Recent Developments in the Early Diagnosis and Management of Multiple Sclerosis. Journal of Neuroscience Nursing 42:6, pages 342-353.
Crossref
Crossref
Nasr Farooqi, Bruno Gran & Cris S. Constantinescu. (2010) Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?. Journal of Neurochemistry 115:4, pages 829-844.
Crossref
Crossref
S. Schmidt. (2010) Cladribin-Tabletten bei schubförmiger Multipler SkleroseOral cladribine for relapsing-remitting multiple sclerosis. Der Nervenarzt 81:10, pages 1231-1241.
Crossref
Crossref
Donald J. AbrahamWilliam A. Denny. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
83
150
.
Reza Vosoughi & Mark S. Freedman. (2010) Therapy of MS. Clinical Neurology and Neurosurgery 112:5, pages 365-385.
Crossref
Crossref
Gavin Giovannoni. (2010) Recent developments in oral medications for the treatment of multiple sclerosis. Future Neurology 5:2, pages 167-172.
Crossref
Crossref
Hans-Peter Hartung, Orhan Aktas, Bernd Kieseier & Giancarlo Comi. (2009) Development of oral cladribine for the treatment of multiple sclerosis. Journal of Neurology 257:2, pages 163-170.
Crossref
Crossref
H.-P. Hartung, B.C. Kieseier & O. Aktas. (2010) CladribinCladribin. Der Nervenarzt 81:2, pages 194-202.
Crossref
Crossref
Michael NamakaChristine Leong, Michael Prout, Josee-Anne Le Dorze, Mike LimerickEmma Frost & Farid Esfahani. (2010) Emerging Therapies for the Management of Multiple Sclerosis. Clinical Medicine Insights: Therapeutics 2, pages CMT.S2213.
Crossref
Crossref
Joseph M. Antony & Christopher Power. 2016. Inflammatory Diseases of the Central Nervous System. Inflammatory Diseases of the Central Nervous System
245
260
.
. 2016. Inflammatory Diseases of the Central Nervous System. Inflammatory Diseases of the Central Nervous System
201
260
.
J.N. Latosińska, M. Latosińska, J. Seliger, V. Žagar & Z. Kazimierczuk. (2009) Electron density distribution in cladribine (2-chloro-2′-deoxyadenosine) – A drug against leukemia and multiple sclerosis – Studied by multinuclear NQR spectroscopy and DFT calculations. Chemical Physics Letters 476:4-6, pages 293-302.
Crossref
Crossref
Z Stelmasiak, J Solski, J Nowicki, B Jakubowska, M Ryba & P Grieb. (2009) Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Multiple Sclerosis Journal 15:6, pages 767-770.
Crossref
Crossref
Melody Ryan. (2009) Drug Therapies for the Treatment of Multiple Sclerosis. Journal of Infusion Nursing 32:3, pages 137-144.
Crossref
Crossref
Hans-Peter Hartung. (2009) New oral therapies may offer improved treatment options for patients with multiple sclerosis. Current Opinion in Neurology 22:Suppl 1, pages S10-S14.
Crossref
Crossref
Patricia K Coyle. (2009) Existing therapies for multiple sclerosis offer proven efficacy and safety. Current Opinion in Neurology 22:Suppl 1, pages S4-S9.
Crossref
Crossref
Kathleen Costello & Jack C. Sipe. (2008) Cladribine Tabletsʼ Potential in Multiple Sclerosis Treatment. Journal of Neuroscience Nursing 40:5, pages 275-280.
Crossref
Crossref
Manuel Comabella. (2008) Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. Therapy 5:5, pages 623-629.
Crossref
Crossref
Tracy DeAngelis & Fred Lublin. (2008) Multiple sclerosis: new treatment trials and emerging therapeutic targets. Current Opinion in Neurology 21:3, pages 261-271.
Crossref
Crossref
Tracy DeAngelis & Fred Lublin. (2008) Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:2, pages 157-167.
Crossref
Crossref